Even mild COVID-19 may induce long-lasting antibody response
So they were wrong yet again. Or they lied in order to get people to take the vaccine. Either one.
Mild cases of COVID-19 leave people with long-term antibody protection against reinfection, according to a new study that challenges previous findings.
“Last fall, there were reports that antibodies wane quickly after infection with the virus that causes COVID-19, and mainstream media interpreted that to mean that immunity was not long-lived,” said study senior author Ali Ellebedy, an associate professor of pathology and immunology, medicine and molecular microbiology at Washington University School of Medicine in St. Louis.
“But that’s a misinterpretation of the data. It’s normal for antibody levels to go down after acute infection, but they don’t go down to zero; they plateau,” Ellebedy said in a university news release. “Here, we found antibody-producing cells in people 11 months after first symptoms. These cells will live and produce antibodies for the rest of people’s lives. That’s strong evidence for long-lasting immunity.”